Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Better Therapeutics, Inc.
  6. Summary
    BTTX   US08773T1043

BETTER THERAPEUTICS, INC.

(BTTX)
  Report
Delayed Nasdaq  -  04:00 2022-06-28 pm EDT
1.690 USD   -6.11%
06/16Better Therapeutics to Participate in Cowen 7th Annual FutureHealth Conference
BU
06/13BETTER THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
06/09Better Therapeutics to Participate in Cowen's Unlocking the Value of Digital Prescription Therapeutics Webinar on June 16, 2022
BU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/22/2022 06/23/2022 06/24/2022 06/27/2022 06/28/2022 Date
1.84(c) 1.88(c) 1.87(c) 1.8(c) 1.69 Last
1 639 544 746 894 444 527 299 100 293 291 Volume
+23.49% +2.17% -0.53% -3.74% -6.11% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -40,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,97x
Yield 2022 -
Sales 2023 3,76 M - -
Net income 2023 -126 M - -
Net Debt 2023 - - -
P/E ratio 2023 -0,40x
Yield 2023 -
Capitalization 39,9 M 39,9 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 10,6x
Nbr of Employees 44
Free-Float 44,9%
More Financials
Company
Better Therapeutics, Inc, is a prescription digital therapeutics (PDT) company. The Company is engaged in developing a novel form of cognitive-behavioral therapy to address the root causes of cardiometabolic diseases. The Company's Nutritional Cognitive Behavioral Therapy (Nutritional CBT) is a novel form of behavioral therapy for patients with type 2 diabetes and other cardiometabolic diseases. It targets the... 
Read more
More about the company
Ratings of Better Therapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about BETTER THERAPEUTICS, INC.
06/16Better Therapeutics to Participate in Cowen 7th Annual FutureHealth Conference
BU
06/13BETTER THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of Matte..
AQ
06/09Better Therapeutics to Participate in Cowen's Unlocking the Value of Digital Prescripti..
BU
06/08Better Therapeutics Issued US Patent for Features of Prescription Digital Therapeutics ..
MT
06/08Better Therapeutics Announces Issuance of U.S. Patent Covering Key Features of Their Pr..
BU
06/07Better Therapeutics Hires Former Myovant Sciences CFO Frank Karbe as Chief Executive
MT
06/07BETTER THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/07Better Therapeutics Appoints Frank Karbe as Chief Executive Officer
BU
06/07Better Therapeutics, Inc. Appoints Frank Karbe as President and as Member of the Board ..
CI
06/07Better Therapeutics Appoints Frank Karbe as Chief Executive Officer Starting July 5, 20..
CI
05/25Top Premarket Decliners
MT
05/19Better Therapeutics to Host Virtual Educational Webinar Symposium on New American Diabe..
BU
05/13BETTER THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
05/13Better Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31..
CI
05/13Better Therapeutics Reports First Quarter 2022 Financial Results and Provides Update on..
BU
More news
News in other languages on BETTER THERAPEUTICS, INC.
06/08Better Therapeutics a obtenu un brevet américain pour les caractéristiques de la platef..
06/07Better Therapeutics engage l'ancien directeur financier de Myovant Sciences, Frank Karb..
06/07Better Therapeutics, Inc. nomme Frank Karbe comme président et membre du conseil d'admi..
06/07Better Therapeutics nomme Frank Karbe au poste de directeur général à compter du 5 juil..
05/13Better Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 ma..
More news
Analyst Recommendations on BETTER THERAPEUTICS, INC.
More recommendations
Chart BETTER THERAPEUTICS, INC.
Duration : Period :
Better Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BETTER THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,69 $
Average target price 17,00 $
Spread / Average Target 906%
EPS Revisions
Managers and Directors
Kevin J. Appelbaum President, Chief Executive Officer & Director
Mark Heinen Chief Financial Officer & Head-Finance
David P. Perry Executive Chairman
Mark Berman Chief Medical Officer
Andres Camacho Senior Vice President-Technology
Sector and Competitors
1st jan.Capi. (M$)
BETTER THERAPEUTICS, INC.-59.78%44
MODERNA, INC.-43.20%57 385
IQVIA HOLDINGS INC.-24.22%40 468
LONZA GROUP AG-32.64%39 851
SEAGEN INC.16.00%33 010
CELLTRION, INC.-11.87%18 371